Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05243628 · ClinicalTrials.gov registry record · Phase 4
Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetes
A Phase 4 study, sponsored by Mannkind Corporation.
- Completed
- Registry status
- Phase 4
- Development phase
- 33
- Enrollment target
NCT05243628: Completed Phase 4 study, sponsored by Mannkind Corporation.
NCT05243628 is a Phase 4 study that has completed, run by Mannkind Corporation. The registered enrollment target is 33 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05243628, a Phase 4 study, has completed, sponsored by Mannkind Corporation.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 33 participants
- Enrollment target
Study Summary
A phase 4 study evaluating the efficacy of mealtime control with Afrezza in combination with an automated insulin pump or insulin degludec in adult subjects with type 1 diabetes
Primary Outcome
Change in glycated hemoglobin (HbA1c) from baseline to end of study
Interventions
- BIOLOGICAL insulin degludec
- BIOLOGICAL Afrezza (insulin human) Inhalation Powder
- DEVICE Continuous Subcutaneous Insulin Infusion (CSII) pump with Automatic Insulin Delivery (AID)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2022-03-31 |
| Est. Completion | 2022-10-17 |
| Phase | Phase 4 |
What the finished NCT05243628 record still lists
NCT05243628 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 3 interventions - of which insulin degludec is the first listed.
NCT05243628 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05243628 about?
NCT05243628 is a clinical study titled "Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetes". A phase 4 study evaluating the efficacy of mealtime control with Afrezza in combination with an automated insulin pump or insulin degludec in adult subjects with type 1 diabetes
What is the current status of trial NCT05243628?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 33 participants. The study started on 2022-03-31. Estimated completion is 2022-10-17.
What interventions are being tested in trial NCT05243628?
The interventions under investigation include: insulin degludec (BIOLOGICAL), Afrezza (insulin human) Inhalation Powder (BIOLOGICAL), Continuous Subcutaneous Insulin Infusion (CSII) pump with Automatic Insulin Delivery (AID) (DEVICE).
Who is sponsoring clinical trial NCT05243628?
This trial is sponsored by Mannkind Corporation, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05243628's enrollment target sits among peer trials
33 1528th of 2000 higher than 467 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI